Chronic low‑grade nociceptive activity maintains a tonic calcium influx through Cav1.2 channels in peripheral sensory neurons. This depolarization‑evoked Ca2+ rise activates PKA, which phosphorylates CREB and drives transcription of genes that bolster cellular repair, immune surveillance and metabolic recalibration. Many of these CREB‑dependent targets overlap with the FOXO‑ and Nrf2‑regulated stress‑response networks that are known to extend lifespan when persistently active in model organisms. Epidemiological data show that older adults routinely use NSAIDs and other analgesics to suppress pain, yet no study has tested whether blunt­ing this physiological calcium signal erodes the very transcriptional programs that preserve stress resistance.

We hypothesize that habitual analgesic exposure reduces Cav1.2‑mediated Ca2+ spikes, lowering PKA‑CREB signaling and consequently diminishing FOXO nuclear translocation and Nrf2‑dependent antioxidant expression. The resulting hypo‑activity of these transcription factors accelerates the genetically‑programmed inactivation of stress‑resistance pathways described in aging literature, leading to earlier onset of epigenetic drift, increased frailty and shortened healthspan. In other words, analgesics may convert a hormetic nociceptive cue into a silent driver of aging.

This hypothesis is testable and falsifiable through complementary human and animal approaches. In a longitudinal cohort of adults aged 60‑80, we would quantify habitual NSAID/acetaminophen use via pharmacy records, assess pain sensitivity with quantitative sensory testing, and measure peripheral blood markers of stress‑response activation (phospho‑CREB, FOXO3 nuclear localization, Nrf2 target gene expression, SIRT1 activity) alongside epigenetic clocks (Horvath, GrimAge) and frailty indices. We predict that higher analgesic burden correlates with reduced CREB/FOXO/Nrf2 signaling, advanced epigenetic age and increased frailty, independent of baseline pain levels or comorbidities.

Parallel experiments in mice would provide causal evidence. Wild‑type mice receiving chronic low‑dose ibuprofen in drinking water (mirroring human therapeutic exposure) would be compared to vehicle‑treated controls. We would monitor lifespan, healthspan metrics (grip strength, treadmill endurance, glucose tolerance), and tissue‑specific readouts of CREB phosphorylation, FOXO activity and Nrf2 target expression in liver, muscle and sensory ganglia. Additionally, we would use a Cre‑lox Cav1.2 knockout restricted to nociceptors to phenocopy analgesic suppression; if the hypothesis holds, both pharmacological and genetic attenuation of Cav1.2 signaling should blunt stress‑response gene induction after mild heat or oxidative challenge and shorten survival relative to wild‑type littermates.

Falsification would occur if analgesic exposure fails to alter CREB/FOXO/Nrf2 activity, epigenetic age or lifespan despite robust pain suppression, or if enhancing Cav1.2 signaling in analgesic‑treated animals rescues stress‑response markers without affecting pain perception. Such outcomes would refute the notion that nociceptive calcium flux serves as a longevity‑promoting signal whose pharmacological silencing drives accelerated aging.

By linking a ubiquitous pharmacologic intervention to a defined transcriptional mechanism, this work would redirect geroscience toward evaluating whether the pursuit of pain‑free longevity inadvertently undermines the very stress‑response circuitry that sustains it.